Chabiotech Co.,Ltd.

Action · KR7085660009 (XKOS)

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur Chabiotech Co.,Ltd.

Pas de cours

Cours de clôture XKOS 29.04.2026: 17.400,00 KRW

29.04.2026 06:30

Cours actuels de Chabiotech Co.,Ltd.

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
KOSDAQ	085660.KQ	KRW	29.04.2026 06:30	17.400,00 KRW	-130,00 KRW -0,74 %

Flottant et Liquidité des Actions

Flottant Libre 90,80 %

Actions en Flottant 69,39 M

Actions en Circulation 76,43 M

Fonds investis

Les fonds suivants ont investi dans Chabiotech Co.,Ltd. :

Fonds iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF USD (Dist)	Vol. en millions 102,46	Part (%) 0,10 %
Fonds iShares MSCI EM IMI ESG Screened UCITS ETF USD (Dist)	Vol. en millions 49,00	Part (%) 0,02 %
Fonds iShares MSCI EM IMI ESG Screened UCITS ETF USD (Acc)	Vol. en millions 248,03	Part (%) 0,02 %

Profil de l'entreprise pour Chabiotech Co.,Ltd. Action

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare. In addition, the company develops immune cells, such as CBT101 for recurrent glioblastoma and solid cancer, and CBT111 and CAR-NK for solid cancer; and stem cells, including CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for macular degeneration and Stargardt's disease. Further, it offers IVF (fertility) services; cosmetics and cosmetic raw materials; medical devices and supplies; bioinsurance storage; research services; and other services. The company was founded in 2002 and is headquartered in Seoul, South Korea.